NCT04393584View on ClinicalTrials.gov

FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

538

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2026

Conditions
Stomach NeoplasmsGastrointestinal NeoplasmsDocetaxelOxaliplatinFluoruracilIrinotecan Hydrochloride
Interventions
DRUG

Irinotecan

d1 Irinotecan 180mg/m² every two weeks

DRUG

5-FU

d1-2 5-FU 2450 mg/m² every two weeks

DRUG

Leucovorin

d1 Leucovorin 200 mg/m² every two weeks

DRUG

Oxaliplatin

d1 Oxaliplatin 85 mg/m² every two weeks

DRUG

Docetaxel

d1 Docetaxel 50mg/m2 every two weeks

Trial Locations (1)

115478

RECRUITING

Aleksei Kalinin, Moscow

All Listed Sponsors
lead

Blokhin's Russian Cancer Research Center

OTHER